Trial Profile

A double-blind, randomised, placebo controlled single ascending doses (SAD) and multiple ascending dose (MAD) study of MOR106 in healthy volunteers and patients with moderate to severe atopic dermatitis.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MOR 106 (Primary)
Indications Atopic dermatitis; Chronic obstructive pulmonary disease; Osteoarthritis; Osteoporosis; Rheumatoid arthritis
Focus Adverse reactions; First in man
Sponsors Galapagos NV

07 May 2026 According to Galapagos NV media release, Galapagos NV is now called Lakefront Biotherapeutics.
17 Feb 2018 Results presented in the Galapagos NV media release.
17 Feb 2018 Results presented in a MorphoSys Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com